Michael Dörks

Dr. Michael Dörks


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2017 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
MDMichael Dörks
Michael Dörks
KAKatharina Allers
Katharina Allers
GSGuido Schmiemann
Guido Schmiemann
SHStefan Herget‐Rosenthal
Stefan Herget‐Rosenthal
FHFalk Hoffmann
Falk Hoffmann

14 April 2016 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MDMichael Dörks
Michael Dörks
GSGuido Schmiemann
Guido Schmiemann
FHFalk Hoffmann
Falk Hoffmann

11 December 2015 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
MDMichael Dörks
Michael Dörks
SHStefan Herget-Rosenthal
Stefan Herget-Rosenthal
GSGuido Schmiemann
Guido Schmiemann
FHFalk Hoffmann
Falk Hoffmann

1 March 2019 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
MDMichael Dörks
Michael Dörks
KAKatharina Allers
Katharina Allers
FHFalk Hoffmann
Falk Hoffmann

1 March 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
MDMichael Dörks
Michael Dörks
KJKathrin Jobski
Kathrin Jobski
FHFalk Hoffmann
Falk Hoffmann
ADAntonios Douros
Antonios Douros
Purpose: To describe the characteristics of adverse event reporting in the United States (US) Food and Drug Administration Adverse Event Reporting System (FAERS) before and after the outbreak of the COVID‐19 pandemic.Methods: We included all FAERS reports from the US and Canada from November 7, 2019 to July 15, 2020 and divided the study period into three equal time intervals (pre‐pandemic, first pandemic, second pandemic). We focused on methotrexate, a broadly used drug unrelated to COVID‐19, and (hydroxy)chloroquine, another broadly used drug implicated in COVID‐19 treatment. Using descriptive statistics, we compared reporting characteristics before and after the COVID‐19 outbreak.Results: During the study period, 366 998 cases (60% female, median age: 59 years) were submitted to FAERS. The daily median number of reports (1796 in the pre‐pandemic, 1810 in the second pandemic time interval) and other characteristics remained stable. The daily median number of reports for methotrexate decreased from 28 in the pre‐pandemic to 15 in the second pandemic time interval, with no considerable differences in other characteristics. The daily median number of reports for (hydroxy)chloroquine increased slightly from 1 in the pre‐pandemic to 3 in the second pandemic time interval, while there were also changes in the demographics of cases and an increase in the proportion of cases reported by health professionals.Conclusions: The overall reporting to FAERS did not change after the outbreak of the COVID‐19 pandemic. However, some stimulated reporting was observed for (hydroxy)chloroquine, highlighting the need for caution when conducting pharmacovigilance analyses with substances related to COVID‐19.

9 January 2021 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
MDMichael Dörks
Michael Dörks
KJKathrin Jobski
Kathrin Jobski
SHStefan Herget‐Rosenthal
Stefan Herget‐Rosenthal
FHFalk Hoffmann
Falk Hoffmann
ADAntonios Douros
Antonios Douros
There are concerns by the United States Food and Drug Administration (FDA) regarding a potential link between tyrosine kinase inhibitors targeting vascular endothelial growth factor (VEGF‐TKIs) and the risk of aortic dissection. Elevation of blood pressure induced by VEGF‐TKIs has been discussed as part of the pathomechanism. To address this important safety issue, we conducted a large pharmacovigilance study assessing the risk of aortic dissection reporting associated with the use of VEGF‐TKIs, thereby exploring the role of blood pressure. We queried the FDA Adverse Event Reporting System from 2004 to 2019 for reports including VEGF‐TKIs and aortic dissection and estimated reporting odds ratios (RORs) and 95% confidence intervals (CIs) of aortic dissection associated with the use of VEGF‐TKIs. Secondary analyses stratified by the strength of blood pressure elevation (≥10 mmHg vs. <10 mmHg increased systolic or diastolic bloods pressure) and pre‐existing arterial hypertension. There were 81 reports of aortic dissection related to VEGF‐TKIs during the study period. VEGF‐TKIs were associated with an increased risk of aortic dissection reporting (ROR, 4.31; 95% CI, 3.43 to 5.42). The risk was higher among compounds strongly increasing blood pressure (ROR, 5.33; 95% CI, 3.88 to 7.32) than among compounds moderately increasing blood pressure (ROR, 2.79; 95% CI, 1.83 to 4.27). Pre‐existing arterial hypertension did not modify the association. Overall, our study showed an increased risk of aortic dissection reporting associated with the use of VEGF‐TKIs. Blood pressure elevation seems to play a role in the pathophysiology of this adverse effect.